InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,428.79
(
-0.35%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
74.95
(
-0.23%
)
Bitcoin
67,945.39
(
0.19%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

puravida

Send PM Follow Ignore
Followers 36
Posts 1736
Boards Moderated 0
Alias Born 05/13/2011

puravida

Re: None

Thursday, 09/22/2016 3:26:24 PM

Thursday, September 22, 2016 3:26:24 PM

Post# of 80490
The allergan Tobira deal offered a fasinating detail to acquisitions that we rarely discuss Here below is a direct quote from allergens pr

"Allergan will acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones".


These CVRs aren't new but rarely discussed But the premium price of 28-49 bucks is a significant difference

Applying that to Ariad I'll let you use your imagination as pertaining to a takeout offer proposal

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up